We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.
The Bio-medical Research Council (BRC), a part of the Oxford Hospital Radcliffe Trust (OHRT), funds research and many of our staff are involved in BRC research.
Our research is funded from a variety of funders. Their support allows our research to focus on the basic and clinical research domains to accelerate knowledge translation from the bedside to the bench, and back again.
Chair, Specialised Rheumatology CRG
Will acceptance of rituximab treatment for IgG4-RD by NHS England make it easier to treat complicated patients with IgG4-RD in the future? Or do you see further problems emerging?
